Kazuno H - Search Results

1

Combination of pimitespib (TAS-116) with sunitinib is an effective therapy for imatinib-resistant gastrointestinal stromal tumors.

Teranishi R, Takahashi T, Obata Y, Nishida T, Ohkubo S, Kazuno H, Saito Y, Serada S, Fujimoto M, Kurokawa Y, Saito T, Yamamoto K, Yamashita K, Tanaka K, Makino T, Nakajima K, Hirota S, Naka T, Eguchi H, Doki Y. Teranishi R, et al. Among authors: kazuno h. Int J Cancer. 2023 Jun 15;152(12):2580-2593. doi: 10.1002/ijc.34461. Epub 2023 Feb 21. Int J Cancer. 2023. PMID: 36752576

2

Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use.

Ito S, Otsuki S, Ohsawa H, Hirano A, Kazuno H, Yamashita S, Egami K, Shibata Y, Yamamiya I, Yamashita F, Kodama Y, Funabashi K, Kazuno H, Komori T, Suzuki S, Sootome H, Hirai H, Sagara T. Ito S, et al. Among authors: kazuno h. ACS Med Chem Lett. 2023 Mar 10;14(4):396-404. doi: 10.1021/acsmedchemlett.3c00006. eCollection 2023 Apr 13. ACS Med Chem Lett. 2023. PMID: 37077386 Free PMC article.

3

TAS4464, A Highly Potent and Selective Inhibitor of NEDD8-Activating Enzyme, Suppresses Neddylation and Shows Antitumor Activity in Diverse Cancer Models.

Yoshimura C, Muraoka H, Ochiiwa H, Tsuji S, Hashimoto A, Kazuno H, Nakagawa F, Komiya Y, Suzuki S, Takenaka T, Kumazaki M, Fujita N, Mizutani T, Ohkubo S. Yoshimura C, et al. Among authors: kazuno h. Mol Cancer Ther. 2019 Jul;18(7):1205-1216. doi: 10.1158/1535-7163.MCT-18-0644. Epub 2019 May 15. Mol Cancer Ther. 2019. PMID: 31092565

4

Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2'-deoxy-5-fluorouridine into DNA.

Sakamoto K, Yokogawa T, Ueno H, Oguchi K, Kazuno H, Ishida K, Tanaka N, Osada A, Yamada Y, Okabe H, Matsuo K. Sakamoto K, et al. Among authors: kazuno h. Int J Oncol. 2015;46(6):2327-34. doi: 10.3892/ijo.2015.2974. Epub 2015 Apr 20. Int J Oncol. 2015. PMID: 25901475 Free PMC article.

5

Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models.

Tanaka N, Sakamoto K, Okabe H, Fujioka A, Yamamura K, Nakagawa F, Nagase H, Yokogawa T, Oguchi K, Ishida K, Osada A, Kazuno H, Yamada Y, Matsuo K. Tanaka N, et al. Among authors: kazuno h. Oncol Rep. 2014 Dec;32(6):2319-26. doi: 10.3892/or.2014.3487. Epub 2014 Sep 17. Oncol Rep. 2014. PMID: 25230742 Free PMC article.

6

The novel VEGF receptor/MET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile.

Fujita H, Miyadera K, Kato M, Fujioka Y, Ochiiwa H, Huang J, Ito K, Aoyagi Y, Takenaka T, Suzuki T, Ito S, Hashimoto A, Suefuji T, Egami K, Kazuno H, Suda Y, Nishio K, Yonekura K. Fujita H, et al. Among authors: kazuno h. Mol Cancer Ther. 2013 Dec;12(12):2685-96. doi: 10.1158/1535-7163.MCT-13-0459. Epub 2013 Oct 18. Mol Cancer Ther. 2013. PMID: 24140932

7

1-(3-C-Ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106), a novel potent inhibitor of RNA polymerase, potentiates the cytotoxicity of CDDP in human cancer cells both in vitro and in vivo.

Kazuno H, Fujioka A, Fukushima M, Wataya Y, Matsuda A, Sasaki T. Kazuno H, et al. Int J Oncol. 2009 May;34(5):1373-80. Int J Oncol. 2009. PMID: 19360349

8

Mechanism of action of a new antitumor ribonucleoside, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106), differs from that of 5-fluorouracil.

Kazuno H, Shimamoto Y, Tsujimoto H, Fukushima M, Matsuda A, Sasaki T. Kazuno H, et al. Oncol Rep. 2007 Jun;17(6):1453-60. Oncol Rep. 2007. PMID: 17487404

9

Possible antitumor activity of 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106) against an established gemcitabine (dFdCyd)-resistant human pancreatic cancer cell line.

Kazuno H, Sakamoto K, Fujioka A, Fukushima M, Matsuda A, Sasaki T. Kazuno H, et al. Cancer Sci. 2005 May;96(5):295-302. doi: 10.1111/j.1349-7006.2005.00046.x. Cancer Sci. 2005. PMID: 15904471 Free article.

10

Synthesis and evaluation of 6-methylene-bridged uracil derivatives. Part 2: optimization of inhibitors of human thymidine phosphorylase and their selectivity with uridine phosphorylase.

Yano S, Kazuno H, Sato T, Suzuki N, Emura T, Wierzba K, Yamashita J, Tada Y, Yamada Y, Fukushima M, Asao T. Yano S, et al. Among authors: kazuno h. Bioorg Med Chem. 2004 Jul 1;12(13):3443-50. doi: 10.1016/j.bmc.2004.04.046. Bioorg Med Chem. 2004. PMID: 15186830

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

33 results

Search Page